
    
      This is a single-centre prospective observational study. Twenty infertile male patients.

      Inclusion criteria are:

      Age:18-50 years oligozoospermia: < 5 million spermatozoa/mL; asthenozoospermia: < 32%
      progressive motile spermatozoa; teratozoospermia: < 4% normal forms.

      Esclusion criteria:

      Patients with azoospermia, who smoke, use drugs, drugs with proven fertility toxicity,
      exposed to any environmental or occupational toxic substances, radiation or heat; with
      orchitis secondary to mumps, sexually transmitted diseases, history of cryptorchidism,
      previous testicular torsion, genitourinary anomalies, alterations of the epididymis or
      deferens; and inguinal surgery

      Pretreatment evaluation included:

      Semen analysis Hormonal determinations:follicle-stimulating hormone (FSH) and luteinising
      hormone (LH) total Testosterone Total,estradiol, prolactina, 25-OH-Vitamin D3); scrotal
      ultrasound prostatic transrectal ultrasound

      Outocmes measures (baseline, at 1 and 6 months):

        -  Semen volume (mL)

        -  Total sperm number (106/ejaculate)

        -  Sperm concentration (106/mL)

        -  Total motility (PR + NP)

        -  Progressive motility (PR, %)

        -  Vitality (live spermatozoa, %)

        -  Sperm morphology (normal forms, %)

        -  Ph

        -  FSH

        -  LH

        -  Testosterone totale

        -  Estradiol

        -  Prolactiona

        -  25-OH-Vitamin D3

        -  scrotal ultrasound

        -  prostatic transrectal ultrasound
    
  